MBIO
Price
$0.44Alerts
Change
-$0.01 (-2.22%)
Updated
Nov 11 closing price
Capitalization
3.01M
2 days until earnings call
Intraday BUY SELL Signals
SCNI
Price
$0.51Alerts
Change
+$0.02 (+4.08%)
Updated
Nov 11 closing price
Capitalization
298.81K
Intraday BUY SELL Signals
Interact to see
Advertisement

MBIO vs SCNI

MBIO vs SCNI Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
MBIO vs. SCNI commentary
Nov 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MBIO is a StrongBuy and SCNI is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for MBIO with price predictions
Nov 10, 2026

MBIO in +5.73% Uptrend, growing for three consecutive days on November 02, 2026

Moving higher for three straight days is viewed as a bullish sign. Keep an eye on this stock for future growth. Considering data from situations where MBIO advanced for three days, in 147 of 191 cases, the price rose further within the following month. The odds of a continued upward trend are 77%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Indicator points to a transition from a downward trend to an upward trend -- in cases where MBIO's RSI Indicator exited the oversold zone, 45 of 59 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 76%.

The Momentum Indicator moved above the 0 level on October 29, 2026. You may want to consider a long position or call options on MBIO as a result. In 58 of 76 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 76%.

The Moving Average Convergence Divergence (MACD) for MBIO just turned positive on October 27, 2026. Looking at past instances where MBIO's MACD turned positive, the stock continued to rise in 27 of 39 cases over the following month. The odds of a continued upward trend are 69%.

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 31 of 31 cases where MBIO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where MBIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

MBIO broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for MBIO entered a downward trend on November 05, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Price Growth Rating for this company is 79 (best 1 - 100 worst), indicating slightly worse than average price growth. MBIO’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of 88 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.398) is normal, around the industry mean (3.498). P/E Ratio (-0.945) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. MBIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

A.I.Advisor
a Summary for SCNI with price predictions
Nov 10, 2026

SCNI in upward trend: price may jump up because it broke its lower Bollinger Band on October 16, 2026

SCNI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 34 of 39 cases where SCNI's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where SCNI's RSI Indicator exited the oversold zone, 34 of 41 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.

The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 66 of 83 cases where SCNI's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 80%.

Following a +12.22% 3-day Advance, the price is estimated to grow further. Considering data from situations where SCNI advanced for three days, in 149 of 197 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SCNI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for SCNI entered a downward trend on November 10, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Valuation Rating of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.049) is normal, around the industry mean (3.498). P/E Ratio (0.016) is within average values for comparable stocks, (-1.193). Projected Growth (PEG Ratio) (0.040) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (130.981) among similar stocks. P/S Ratio (0.536) is also within normal values, averaging (440.869).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is 97 (best 1 - 100 worst), indicating slightly worse than average price growth. SCNI’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. SCNI’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 93, placing this stock worse than average.

FUNDAMENTALS RATINGS
MBIO vs SCNI: Fundamental Ratings
MBIO
SCNI
OUTLOOK RATING
1..100
1648
VALUATION
overvalued / fair valued / undervalued
1..100
88
Overvalued
50
Fair valued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9812
PRICE GROWTH RATING
1..100
7997
P/E GROWTH RATING
1..100
9897
SEASONALITY SCORE
1..100
4750

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SCNI's Valuation (50) in the Pharmaceuticals Major industry is somewhat better than the same rating for MBIO (88). This means that SCNI’s stock grew somewhat faster than MBIO’s over the last 12 months.

SCNI's Profit vs Risk Rating (100) in the Pharmaceuticals Major industry is in the same range as MBIO (100). This means that SCNI’s stock grew similarly to MBIO’s over the last 12 months.

SCNI's SMR Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for MBIO (98). This means that SCNI’s stock grew significantly faster than MBIO’s over the last 12 months.

MBIO's Price Growth Rating (79) in the Pharmaceuticals Major industry is in the same range as SCNI (97). This means that MBIO’s stock grew similarly to SCNI’s over the last 12 months.

SCNI's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as MBIO (98). This means that SCNI’s stock grew similarly to MBIO’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MBIOSCNI
RSI
ODDS (%)
Bullish Trend 2 days ago
76%
Bullish Trend 2 days ago
83%
Stochastic
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
76%
N/A
MACD
ODDS (%)
Bullish Trend 2 days ago
69%
N/A
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
73%
Bullish Trend 2 days ago
78%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
72%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 10 days ago
77%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 8 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
90%
Bullish Trend 2 days ago
87%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
COMPARISON
Comparison
Nov 12, 2026
Stock price -- (MBIO: $0.45 vs. SCNI: $0.49)
Brand notoriety: MBIO and SCNI are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MBIO: 519% vs. SCNI: 6%
Market capitalization -- MBIO: $3.01M vs. SCNI: $298.81K
MBIO [@Biotechnology] is valued at $3.01M. SCNI’s [@Biotechnology] market capitalization is $298.81K. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The average market capitalization across the [@Biotechnology] industry is $2.23B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MBIO’s FA Score shows that 0 FA rating(s) are green while SCNI’s FA Score has 1 green FA rating(s).

  • MBIO’s FA Score: 0 green, 5 red.
  • SCNI’s FA Score: 1 green, 4 red.
According to our system of comparison, SCNI is a better buy in the long-term than MBIO.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MBIO’s TA Score shows that 4 TA indicator(s) are bullish while SCNI’s TA Score has 4 bullish TA indicator(s).

  • MBIO’s TA Score: 4 bullish, 4 bearish.
  • SCNI’s TA Score: 4 bullish, 2 bearish.
According to our system of comparison, SCNI is a better buy in the short-term than MBIO.

Price Growth

MBIO (@Biotechnology) experienced а +10.06% price change this week, while SCNI (@Biotechnology) price change was +7.96% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +4.90%. For the same industry, the average monthly price growth was -2.72%, and the average quarterly price growth was -13.41%.

Reported Earning Dates

MBIO is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (+4.90% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
Interact to see
Advertisement

MBIO and

Correlation & Price change

A.I.dvisor indicates that over the last year, MBIO has been loosely correlated with MDGL. These tickers have moved in lockstep 50% of the time. This A.I.-generated data suggests there is some statistical probability that if MBIO jumps, then MDGL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MBIO
1D Price
Change %
MBIO100%
+15.13%
MDGL - MBIO
50%
Loosely correlated
-0.04%
ORMP - MBIO
44%
Loosely correlated
-0.75%
AXON - MBIO
40%
Loosely correlated
-0.21%
SCNI - MBIO
38%
Loosely correlated
+7.03%
MIRM - MBIO
34%
Loosely correlated
+1.33%
More

SCNI and

Correlation & Price change

A.I.dvisor indicates that over the last year, SCNI has been closely correlated with TAOX. These tickers have moved in lockstep 73% of the time. This A.I.-generated data suggests there is a high statistical probability that if SCNI jumps, then TAOX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SCNI
1D Price
Change %
SCNI100%
+7.03%
TAOX - SCNI
73%
Closely correlated
-5.15%
MBIO - SCNI
37%
Loosely correlated
+15.13%
VANI - SCNI
32%
Poorly correlated
+2.22%
BDRX - SCNI
32%
Poorly correlated
+2.03%
BYSI - SCNI
32%
Poorly correlated
-6.05%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
ZENA0.700.04
+5.33%
ZenaTech Inc.
AMG401.3218.17
+4.74%
Affiliated Managers Group
YMT0.26N/A
+0.08%
Yimutian Inc
XXI5.32-0.25
-4.49%
Twenty One Capital Inc.
SHOE14.57-0.87
-5.63%
Shoe Station Group Inc